The company held 2016 annual board of directors, board of supervisors
Release time:
2020-08-14
Company Held 2016 Board of Directors and Board of Supervisors
to Review and Pass the Board's Work Report and Other Proposals and Reports
News 4# November 15 , the 11 Meeting of the 9th Board of Directors of the Group Company was held in Jianfeng Building, deliberated and passed 2016 Board of Directors Work Report, 2016 General Manager Work Report and other 14 proposals and reports. The
meeting was presided over by Jiang Xiaomeng, chairman of the group company. Yu Jianhong, general manager, made an annual work report on behalf of the management team, comprehensively summarizing and reviewing the company's 2016 work.
In 2016 , the company focused on the general policy of "innovation, integration, improvement, and development", actively sought new opportunities for development, made new breakthroughs in cooperative innovation, carried out in-depth management integration, continuously improved management levels, and strengthened marketing Management and market expansion have achieved steady growth in product sales, technological innovation and technological transformation have achieved obvious results, and corporate image and influence have been effectively improved. The company realized operating income of 23.79 .2 billion yuan for the whole year, up 5.34% year on year. Net profit attributable to owners of the parent company 28522.95 yuan, up 41.98% year on year, the highest level in history. By the end of 2016 , the company's total assets were 39.95 .2 billion yuan, up 10% year on year. Net assets were 25.52 .6 billion yuan, up 9.82 year on year.
2016 , thanks to the national strategy of "the belt and road initiative", the national cement production increased by 2.3% year-on-year, driven by the recovery of infrastructure investment and real estate investment. The growth of total demand, the development and construction of the southwest region and the implementation of a series of structural reform measures on the supply side of the cement industry, including peak production, industry self-discipline and market integration, cement prices rebounded after bottoming out in the first half of 2016 , and the cement industry in some areas improved. The company's cement business sector seized the opportunity of supply-side reform, actively advocated industry self-discipline, and worked closely around the cost-leading strategy. Daye Peak actively participated in large-scale project bidding while increasing the expansion of the civil market for bagged cement, striving to maintain the gross profit level of tons of cement and ensuring the balance of production and sales in the off-season market. Yunnan Peak strives to enhance the brand status of Peak Cement and advocates self-discipline in the cement industry in southwest Yunnan, actively develop key projects, continue to expand market share, and significantly improve economic efficiency.
Peak Pharmaceutical strives to seek new projects and make new breakthroughs according to strategic planning. In terms of business development, Jianfeng Pharmaceutical has introduced advanced German technology and established a Sino-German joint venture Zhejiang Jindal Baby Drug Co., Ltd. to build a platform specializing in the research and development, production and operation of infant drugs. After more than half a year of research and negotiation, it successfully reached an agreement with Beihui Biology's major shareholders to take a stake in Beihui Biology by way of capital increase and equity transfer. In terms of equity investment, the company also completed the capital increase of Peak Pharmaceuticals and Tianshili Group. In terms of product sales, efforts have been made to realize the entry of peak pharmaceutical products into various catalogues. Jinhua Pharmaceutical Company has obtained the qualification of main distribution in Yiwu primary hospitals. Peak pharmacy has added 4 chain stores and 4 designated medical insurance pharmacies, realizing sales growth. In terms of technological innovation, the research and development project of Jianfeng Pharmaceutical's new anti-tumor drug DPT (deoxypodophyllotoxin) is progressing smoothly, and it has obtained clinical trial approval documents issued by CFDA and obtained a number of related invention patents.
peak health food extraction workshop passed GMP certification, extraction workshop passed Kosher (clean food), halal (halal) certification, and passed ISO9001 , ISO22000 system on-site audit; Complete the drug production record of Ginkgo biloba extract and the establishment of GMP management system, complete the certification of SC for 5 unit foods such as jelly, flavored tea, plant beverages, etc. Tianjin Jianfeng Natural Products Company has strengthened the development of the domestic market while continuing to expand the international market, realizing the simultaneous growth of international and domestic market sales. Peak cable through the product system, Ter and other certification supervision and inspection, large logarithmic cable successfully entered the Hangzhou G20 project. At the same time, the company takes budget management and benchmarking management as the guidance, fine management and PDCA
also deliberated and approved the "plan on profit distribution for 2016
2016 , based on 2016 year-end share capital ,344,083, 828 shares, and distribute cash dividend 2.5 yuan (including tax) for every 10 shares, the total amount of cash dividends distributed to all shareholders registered on the date of record is 86,020,957.00 yuan (including tax), and 2016 will not be converted into share capital. The distribution plan still needs to be approved by the general meeting of shareholders. If it is implemented, the cash dividend accumulated by the company to shareholders in the last three years will reach 23397.70 .14 million yuan. On the same day, 115 , the company also held the 119 meeting of the 10th 118 of the 8th board of supervisors, deliberated and passed the 123 proposals and reports of the 5th board of supervisors of the company 2016 and the proposal on adding supervisors. (Zhou Hengbin)
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page